Notice of Interim Results and Presentations
Belfast and London, 5 September 2023 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharmaceutical industry, today confirms that it will announce its unaudited results for the six months ended 30 June 2023 on Tuesday, 26 September 2023.
Analyst Presentation
A webinar presentation for analysts will be held at 10.00am on Tuesday, 26 September 2023 via the London Stock Exchange's SparkLive platform. Those wishing to attend can register using the following link:
https://www.lsegissuerservices.com/spark/Diaceutics/events/3e138a9b-2f9d-4adf-b5e0-790cb1f39b49
Investor Presentation
Peter Keeling (CEO), Nick Roberts (CFO) and Ryan Keeling (CIO) will also provide a live presentation relating to the Company's results via the Investor Meet Company platform on Tuesday 26 September 2023 at 4.30pm.
The presentation is open to all existing and potential shareholders and registration can be completed via the following link:
https://www.investormeetcompany.com/diaceutics-plc/register-investor
Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9.00am the day before the meeting or at any time during the live presentation. Investors who already follow Diaceutics on the Investor Meet Company platform will automatically be invited.
Enquiries:
| Diaceutics PLC | |
| Peter Keeling, Chief Executive Officer | Tel: +44 (0)28 9040 6500 |
| Ryan Keeling, Chief Innovation Officer | investorrelations@diaceutics.com |
| Nick Roberts, Chief Financial Officer | |
| | |
| Stifel Nicolaus Europe Limited (Nomad & Broker) | Tel: +44 (0)20 7710 7600 |
| Ben Maddison | |
| Nick Harland | |
| Kate Hanshaw | |
| | |
| Alma PR | Tel: +44(0)20 3405 0205 |
| Caroline Forde | diaceutics@almapr.co.uk |
| Matthew Young | |
| Kinvara Verdon | |
About Diaceutics
At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world's leading pharmaceutical and life science companies with solutions and technology for the commercialisation of their precision medicines, enabled by our proprietary DXRX platform.
DXRX is the world's first diagnostic commercialisation platform for precision medicine, utilising a global network of affiliate laboratories to deliver multiple pipelines of real-world healthcare data insights, advisory services and innovative platform enabled solutions.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
